Epizyme (EPZM) Rating Lowered to Sell at BidaskClub

Share on StockTwits

BidaskClub lowered shares of Epizyme (NASDAQ:EPZM) from a hold rating to a sell rating in a report published on Wednesday.

Several other research analysts have also recently weighed in on EPZM. Roth Capital set a $24.00 price target on shares of Epizyme and gave the stock a buy rating in a report on Tuesday, April 24th. ValuEngine upgraded shares of Epizyme from a strong sell rating to a sell rating in a report on Wednesday, May 9th. Wedbush cut their price target on shares of Epizyme from $24.00 to $20.00 and set an outperform rating on the stock in a report on Tuesday, April 24th. SunTrust Banks cut their price target on shares of Epizyme to $20.00 and set a hold rating on the stock in a report on Tuesday, April 24th. Finally, Zacks Investment Research cut shares of Epizyme from a buy rating to a hold rating in a report on Friday, March 16th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company’s stock. Epizyme presently has a consensus rating of Buy and a consensus price target of $23.00.

Epizyme stock opened at $14.80 on Wednesday. Epizyme has a fifty-two week low of $11.15 and a fifty-two week high of $21.40.

Epizyme (NASDAQ:EPZM) last released its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.05. During the same quarter in the previous year, the firm earned ($0.56) EPS. equities research analysts forecast that Epizyme will post -2.22 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quantbot Technologies LP purchased a new position in Epizyme in the first quarter valued at about $111,000. Principal Financial Group Inc. purchased a new position in Epizyme in the first quarter valued at about $187,000. Teacher Retirement System of Texas purchased a new position in Epizyme in the fourth quarter valued at about $202,000. Element Capital Management LLC purchased a new position in Epizyme in the first quarter valued at about $207,000. Finally, MetLife Investment Advisors LLC purchased a new position in Epizyme in the fourth quarter valued at about $263,000. Hedge funds and other institutional investors own 85.22% of the company’s stock.

Epizyme Company Profile

Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply